FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386496821> ?p ?o ?g. }

• W4386496821 abstract "Lifetime cumulative doses of conventional doxorubicin (>450 mg/m2) are associated with dose-dependent cardiotoxicity. In sarcoma and breast cancer, conventional doxorubicin is often utilized in the adjuvant setting, whereas pegylated liposomal doxorubicin (PLD) is typically reserved for recurrent and metastatic disease. PLD is believed to be associated with reduced cardiotoxicity compared to conventional doxorubicin. Limited data exists evaluating the cardiotoxicity associated with PLD treatment after conventional doxorubicin, especially when doxorubicin lifetime doses approach the established cumulative total lifetime dose of 450-550 mg/m2. This study aims to further qualify the cardiac safety of PLD use in patients who have had prior exposure to conventional doxorubicin.This was a single-center, observational, retrospective cohort study conducted in patients ≥18 years with sarcoma or breast cancer who were exposed to conventional doxorubicin from an earlier line of treatment before PLD between January 2010 to May 2022. Patients were evaluated for the presence of cardiac toxicity at any point in their treatment course. Cardiac toxicity was defined as ≥ 10% decrease in left ventricle ejection fraction (LVEF) or a new diagnosis of heart failure within six months after PLD cessation. The time interval between the last conventional doxorubicin exposure and PLD initiation and the time interval between PLD initiation and LVEF monitoring were also analyzed.494 patients were screened, and 50 met inclusion criteria: eight with sarcoma and 42 with breast cancer. The median lifetime cumulative conventional doxorubicin dose in patients with sarcoma was 450 mg/m2 with a maximum dose of 825 mg/m2 and 240 mg/m2 with a maximum dose of 300 mg/m2 in breast cancer patients. The median lifetime cumulative PLD dose was 105 mg/m2 (range: 35-150 mg/m2) in the sarcoma group and 105 mg/m2 (range: 35-510 mg/m2) in the breast cancer group. A decrease of ≥ 10% in LVEF was not observed in the sarcoma group. Patients with breast cancer had available LVEF data on PLD, and three of these patients experienced ≥ 10% in LVEF drop, with one of these patients diagnosed with heart failure. The average cumulative dose of PLD administered in patients with > 10% decrease in LVEF was 177 mg/m2 and had an average of 3.5 cycles. Five sarcoma patients initiated PLD treatment within two years after conventional doxorubicin exposure, while most breast patients initiated PLD treatment at least 10 years following conventional doxorubicin exposure. The average time from PLD initiation to first and second available LVEF monitoring was one and five months in the sarcoma group and three and eight months in the breast cancer group, respectively.PLD administration in patients with prior exposure to conventional doxorubicin appears to be safe, with limited cardiotoxicity in patients with sarcoma and breast cancer. Future research is needed to determine if and how often routine cardiac monitoring is needed for patients on PLD without existing cardiac risk." @default.
• W4386496821 created "2023-09-07" @default.
• W4386496821 creator A5007468276 @default.
• W4386496821 creator A5036199336 @default.
• W4386496821 creator A5041781736 @default.
• W4386496821 creator A5046116123 @default.
• W4386496821 creator A5075878594 @default.
• W4386496821 date "2023-09-07" @default.
• W4386496821 modified "2023-10-11" @default.
• W4386496821 title "Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer" @default.
• W4386496821 cites W1589920570 @default.
• W4386496821 cites W1980428198 @default.
• W4386496821 cites W1999533878 @default.
• W4386496821 cites W2015815662 @default.
• W4386496821 cites W2070825008 @default.
• W4386496821 cites W2093274439 @default.
• W4386496821 cites W2096593771 @default.
• W4386496821 cites W2106810178 @default.
• W4386496821 cites W2126727347 @default.
• W4386496821 cites W2157470118 @default.
• W4386496821 cites W2769852535 @default.
• W4386496821 cites W2891112169 @default.
• W4386496821 cites W2940525953 @default.
• W4386496821 cites W2976051129 @default.
• W4386496821 cites W3024305546 @default.
• W4386496821 cites W3095218433 @default.
• W4386496821 cites W3112448992 @default.
• W4386496821 cites W3136371246 @default.
• W4386496821 doi "https://doi.org/10.7759/cureus.44837" @default.
• W4386496821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37809186" @default.
• W4386496821 hasPublicationYear "2023" @default.
• W4386496821 type Work @default.
• W4386496821 citedByCount "0" @default.
• W4386496821 crossrefType "journal-article" @default.
• W4386496821 hasAuthorship W4386496821A5007468276 @default.
• W4386496821 hasAuthorship W4386496821A5036199336 @default.
• W4386496821 hasAuthorship W4386496821A5041781736 @default.
• W4386496821 hasAuthorship W4386496821A5046116123 @default.
• W4386496821 hasAuthorship W4386496821A5075878594 @default.
• W4386496821 hasBestOaLocation W43864968211 @default.
• W4386496821 hasConcept C121608353 @default.
• W4386496821 hasConcept C126322002 @default.
• W4386496821 hasConcept C142724271 @default.
• W4386496821 hasConcept C143998085 @default.
• W4386496821 hasConcept C151032500 @default.
• W4386496821 hasConcept C2776694085 @default.
• W4386496821 hasConcept C2776802502 @default.
• W4386496821 hasConcept C2778198053 @default.
• W4386496821 hasConcept C2778233292 @default.
• W4386496821 hasConcept C2778256501 @default.
• W4386496821 hasConcept C2781303535 @default.
• W4386496821 hasConcept C530470458 @default.
• W4386496821 hasConcept C71924100 @default.
• W4386496821 hasConcept C78085059 @default.
• W4386496821 hasConceptScore W4386496821C121608353 @default.
• W4386496821 hasConceptScore W4386496821C126322002 @default.
• W4386496821 hasConceptScore W4386496821C142724271 @default.
• W4386496821 hasConceptScore W4386496821C143998085 @default.
• W4386496821 hasConceptScore W4386496821C151032500 @default.
• W4386496821 hasConceptScore W4386496821C2776694085 @default.
• W4386496821 hasConceptScore W4386496821C2776802502 @default.
• W4386496821 hasConceptScore W4386496821C2778198053 @default.
• W4386496821 hasConceptScore W4386496821C2778233292 @default.
• W4386496821 hasConceptScore W4386496821C2778256501 @default.
• W4386496821 hasConceptScore W4386496821C2781303535 @default.
• W4386496821 hasConceptScore W4386496821C530470458 @default.
• W4386496821 hasConceptScore W4386496821C71924100 @default.
• W4386496821 hasConceptScore W4386496821C78085059 @default.
• W4386496821 hasLocation W43864968211 @default.
• W4386496821 hasLocation W43864968212 @default.
• W4386496821 hasOpenAccess W4386496821 @default.
• W4386496821 hasPrimaryLocation W43864968211 @default.
• W4386496821 hasRelatedWork W2053572223 @default.
• W4386496821 hasRelatedWork W2094475704 @default.
• W4386496821 hasRelatedWork W2123912484 @default.
• W4386496821 hasRelatedWork W2170837122 @default.
• W4386496821 hasRelatedWork W2403015684 @default.
• W4386496821 hasRelatedWork W2569855433 @default.
• W4386496821 hasRelatedWork W3011400996 @default.
• W4386496821 hasRelatedWork W4316041250 @default.
• W4386496821 hasRelatedWork W4318478884 @default.
• W4386496821 hasRelatedWork W2157841994 @default.
• W4386496821 isParatext "false" @default.
• W4386496821 isRetracted "false" @default.
• W4386496821 workType "article" @default.